Orion Oyj

ORNBV

FI0009014377

Orion Oyj is Finland's leading pharmaceutical group. Net sales break down by family products and services as follows: - generic, OTC and biosimilar drugs (43.4%); - patented prescription products (41.7%): notably intended for treating dysfunctions of the nervous system, cardiovascular diseases, hormonal and urological treatments; - animal health products (8.7%); - pharmaceutical ingredients and outsourcing services (6.2%). Net sales break down primarily by source of revenue between sales of products (86.9%) and royalties (10.4%). Net sales are distributed geographically as follows: Finland (28%), Scandinavia (12%), Europe (30.8%), North America (14.7%) and other (14.5%).

Employees

3,819

Sector

Pharmaceuticals

Calendar

2024-10-14 - Final dividend

More about the company

Income Statement and Estimates

More financial data

Ratings

Trading Rating

Investor Rating

ESG Refinitiv

A-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

46.39EUR

Average target price

44.33EUR

Spread / Average Target

-4.43%

Consensus

Profit revisions

Estimate revisions

Quarterly earnings, Rate of surprise

Company calendar

Market Closed - Nasdaq Helsinki Other stock markets 12:00:00 2024-09-13 EDT			5-day change	1st Jan Change
46.39 ^EUR	-1.51%		-3.80%	+18.13%

09-13	Danske Bank Downgrades Orion to Hold, Lifts PT	MT
09-11	Orion Lifts FY24 Net Sales, Operating Profit Forecast	MT

Danske Bank Downgrades Orion to Hold, Lifts PT	09-13	MT
Orion Lifts FY24 Net Sales, Operating Profit Forecast	09-11	MT
Orion Oyj Upgrades Earnings Guidance for the Year 2024	09-11	CI
Jefferies Upgrades Orion to Hold, Boosts PT	08-14	MT
Inderes Downgrades Orion to Reduce Rating	08-09	MT
Transcript : Orion Oyj, H1 2024 Earnings Call, Aug 08, 2024	08-08
Orion Oyj Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2024	08-08	CI
Orion Corporation Revises Earnings Guidance for the Year 2024	08-08	CI
Orion Announces Phase III Aranote Trial of Darolutamide in Combination with Androgen Deprivation Therapy in Men with Metastatic Hormone-Sensitive Prostate Cancer Meets Primary Endpoint	07-17	CI
Orion, Merck & Co. Convert Agreement into Exclusive Global License to Opevesostat	07-01	MT
Orion Upgrades FY24 Outlook After Modifying Agreement with Merck & Co	07-01	MT
Merck, Orion Convert Collaboration Into Exclusive License	07-01	DJ
Orion Corporation and MSD Announce Mutual Exercise of Option Providing MSD Global Exclusive Rights to Opevesostat	07-01	CI
Orion Oyj Revises Earnings Guidance for the Year 2024	07-01	CI
Orion Obtains License to Market Navamedic's Parkinson's Disease Drug in Europe	06-25	MT
Navamedic ASA and Orion Corporation Sign License & Supply Agreement for Flexilev in Europe	06-24	CI
Orion Partners with Universities for Biotechnology Project in Finland	06-03	MT
Orion Corporation Announces Change in Orion Group Executive Management Board as of 31 May 2025	05-07	CI
Orion Corporation Announces Appointments to Nomination Committee	04-26	CI
Transcript : Orion Oyj, Q1 2024 Earnings Call, Apr 25, 2024	04-25
Orion Oyj Revises Earnings Guidance for the Year 2024	04-25	CI
Orion Oyj Reports Earnings Results for the First Quarter Ended March 31, 2024	04-25	CI
Orion to Continue Reviewing Outsources Options for Finnish Plant as Change Negotiations Complete	03-22	MT
Orion Corporation Announces Change in Executive Management Board, Effect as of 1 April 2024	03-22	CI
Orion Corporation Announces Board and Committee Appointment	03-20	CI

Orion Oyj

Equities